Table 2.
PK parameters of cefquinome after a single intramuscular administration in catheter-associated biofilm infection model of mice.
| Cefquinome (mg/kg) | T1/2Kel† (h) | T1/2Ka (h) | Tmax (h) | Cmax (μg/mL) | AUC (μg/mL) × h | Vd/F (L/kg) | Cl/F (L/kg × h) |
|---|---|---|---|---|---|---|---|
| 2 | 0.33 | 0.02 | 0.10 | 3.02 | 1.79 | 0.54 | 1.12 |
| 8 | 0.31 | 0.04 | 0.15 | 10.1 | 6.25 | 0.57 | 1.28 |
| 16 | 0.22 | 0.06 | 0.16 | 22.2 | 11.8 | 0.43 | 1.36 |
| 32 | 0.35 | 0.03 | 0.12 | 35.6 | 22.7 | 0.71 | 1.41 |
| 64 | 0.30 | 0.03 | 0.11 | 67.2 | 37.9 | 0.74 | 1.69 |
| 128 | 0.47 | 0.04 | 0.17 | 178.5 | 165.1 | 0.57 | 0.78 |
| 256 | 0.48 | 0.05 | 0.19 | 287.6 | 331.1 | 0.73 | 0.75 |
| Mean ± SD | 0.38 ± 0.14 | 0.04 ± 0.01 | 0.14 ± 0.03 | – | – | 0.61 ± 0.11 | 1.20 ± 0.32 |
†T1/2Kel, elimination half-life; T1/2Ka, absorption half-life; Cmax, peak plasma concentration; Tmax, time of maximum concentration; AUC, total area under the time-concentration curve; Vd/F, volume of distribution during terminal phase as a function of bioavailability; Cl/F, body clearance as a function of bioavailability.